Human IFN-gamma R2 Antibody Summary
Ala22-Gln247
Accession # P38484
Applications
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Scientific Data
Detection of IFN‑ gamma R2 in human blood‑derived granulocytes Blood-derived granulocytes were stained with Goat Anti-Human IFN-gamma R2 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF773, filled histogram) or control antibody (Catalog # AB-108-C, open histogram), followed by Allophycocyanin-conjugated Anti-Goat IgG Secondary Antibody (Catalog # F0108).
IFN‑ gamma Inhibition of EMCV-induced Cytopathy and Neutralization by Human IFN‑ gamma R2 Antibody. Recombinant Human IFN-gamma (Catalog # 285-IF) reduces the Encephalomyocarditis Virus (EMCV)-induced cytopathy in the HeLa human cervical epithelial carcinoma cell line in a dose-dependent manner (orange line). Inhibition of EMCV activity elicited by Recombinant Human IFN-gamma (2 ng/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Human IFN-gamma R2 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF773). The ND50 is typically 0.5-2.5 µg/mL.
Reconstitution Calculator
Preparation and Storage
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: IFN-gamma R2
Interferon gamma Receptor 2 (IFN-gamma R2) is a type II transmembrane protein that associates with IFN-gamma R1 to form a high affinity receptor complex for IFN-gamma. IFN‑ gamma R2 is required for signal transduction but does not bind IFN-gamma by itself.
Product Datasheets
Citations for Human IFN-gamma R2 Antibody
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
4
Citations: Showing 1 - 4
Filter your results:
Filter by:
-
CRISPR activation screen identifies BCL-2 proteins and B3GNT2 as drivers of cancer resistance to T cell-mediated cytotoxicity
Authors: J Joung, PC Kirchgatte, A Singh, JH Cho, SP Nety, RC Larson, RK Macrae, R Deasy, YY Tseng, MV Maus, F Zhang
Nature Communications, 2022-03-25;13(1):1606.
Species: Human
Sample Types: Cell Lysates
Applications: Western Blot -
Glycosylation-Dependent IFN-?R Partitioning in Lipid and Actin Nanodomains Is Critical for JAK Activation
Authors: CM Blouin, Y Hamon, P Gonnord, C Boularan, J Kagan, C Viaris de, R Ruez, S Mailfert, N Bertaux, D Loew, C Wunder, L Johannes, G Vogt, FX Contreras, D Marguet, JL Casanova, C Galès, HT He, C Lamaze
Cell, 2016-08-04;166(4):920-34.
Species: Human
Sample Types: Cell Lysates
Applications: Western Blot -
Trisomy 21 consistently activates the interferon response
Elife, 2016-07-29;5(0):.
Species: Human
Sample Types: Cell Lysates
Applications: Western Blot -
Immunologic analysis of HIV-uninfected Taiwanese children with BCG-induced disease.
Authors: Lee WI, Liang FC, Huang JL, Jaing TH, Wang CH, Lin TY, Huang YC, Huang WL, Jou R, Hsieh MY, Chia JH, Wu TL
J. Clin. Immunol., 2008-12-13;29(3):319-29.
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry
FAQs
No product specific FAQs exist for this product, however you may
View all Antibody FAQsReviews for Human IFN-gamma R2 Antibody
Average Rating: 4 (Based on 1 Review)
Have you used Human IFN-gamma R2 Antibody?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Filter by:
Cancer cells as indicated were treated with or without INF-g (10ng/ml) for 24h. Total cell lysates were subjected to western blot. PVDF membrane were probed with 1mm/ml Human Human IFN-gamma R2 Antibody (AF773). A specific band was detected for IFN-gamma R2 at approximately 40kDa. This experiment was conducted under reducing conditions